大数跨境

【蛋白芯片】eBioMedicine(2023 IF:11.1)| 抗体芯片揭示神药二甲双胍+他汀类药物治疗胶质母细胞瘤机制

【蛋白芯片】eBioMedicine(2023 IF:11.1)| 抗体芯片揭示神药二甲双胍+他汀类药物治疗胶质母细胞瘤机制 丰信生命科学
2023-11-10
1
导读:杂志:eBioMedicine (2023 IF:11.1)发表:2023-04芯片:AAH-PPP-1(55个因子磷酸化抗体芯片)原文:见文中链接


抗体芯片揭示神药二甲双胍+他汀类药物治疗胶质母细胞瘤机制

AAH-PPP-1(55个因子磷酸化抗体芯片)






杂志名称:

eBioMedicine(2023 IF:11.1)


文献题目:

Metformin and simvastatin exert additive antitumour effects in glioblastoma via senescence-state: clinical and translational evidence


第一作者:

Antonio C. Fuentes-Fayos


通讯作者:

Raúl M. Luque


作者单位:

西班牙科尔多瓦麦蒙尼德生物医学研究所(IMIBIC)


发表时间

2023-04


文献全文下载地址:

https://www.sciencedirect.com/science/article/pii/S235239642300049X


本实验所用产品:

品名:Human Phosphorylation Pathway Profiling Array C55 kit

货号:AAH-PPP-1(55个因子磷酸化抗体芯片)

详情:https://www.raybiotech.com/human-phosphorylation-pathway-profiling-array-c55-aah-ppp-1

因子列表:




芯片类型:


实验样本:

细胞裂解液










背景


胶质母细胞瘤(GBM)是最常见的致命的成人原发性脑肿瘤,仅<10%的新发GBM患者存活期可以超过五年。GBM患者的主要治疗方法是手术切除,然后配合放射治疗和辅助治疗(替莫唑胺化疗)。目前针对GBM,没有真正的有效的治疗药物。

二甲双胍和他汀类药物(例如辛伐他汀),通常用于治疗代谢相关疾病(即肥胖、2型糖尿病和高胆固醇血症)已在不同的恶性脑瘤患者中进行了测试。尽管二甲双胍和他汀类药物的抗肿瘤作用仍有争议,但据我们所知,这两种药物的分别使用和联合使用会有抗肿瘤性质,两种药物的抗肿瘤机制目前仍然不明。







思路&结果



1、二甲双胍或辛伐他汀的治疗,特别是它们的联合治疗,降低了不同GBM模型的增殖率,但没有降低非肿瘤对照细胞的存活率


实验用人的GBM细胞系U-87 MG/U-118 MG和患者来源的原代细胞(来自GBM和高级别III型星形细胞瘤(AIII)),正常对照细胞使用人正常脑组织原代细胞培养。分别进行了二甲双胍、辛伐他汀和两种药物联合治疗的剂量依赖和时间依赖的实验。随着两种药物剂量和时间的增加,GBM细胞的存活率越低。二甲双胍和辛伐他汀两种药物的最优浓度分别是10 mM和10 μM。同样的,对患者来源的胶质瘤原代培养细胞也具有类似的存活率显著下降的作用,而对人原代正常脑组织则没有此作用。




2、二甲双胍、辛伐他汀的治疗,特别是它们的联合治疗,改变了细胞体外其他关键功能参数


分别对二甲双胍、辛伐他汀和联合用药前后的GBM细胞的细胞迁移、细胞增殖、瘤体形成、VEGF分泌、衰老相关β半乳糖苷酶、细胞周期、集落形成进行了评估。结果表明,二甲双胍和辛伐他汀治疗会损害GBM细胞的进展,发育和侵袭性,从而在体外诱导衰老表型,并且通常当两种药物联合使用时,这些作用显着增强。




3、二甲双胍和/或辛伐他汀调节GBM细胞中关键致癌途径相关的蛋白质磷酸化水平


用磷酸化蛋白芯片,在U-87MG细胞进行磷酸化分析,二甲双胍和辛伐他汀及其联合用药会产生抗肿瘤作用,相关信号通路受到相应调节。二甲双胍通过激活AMPKa,随即引起下游AKT通路磷酸化水平下调和TP53,MAP14,JNK,和ERK1/ERK2水平上调。同样,辛伐他汀也会引起AKT通路的磷酸化水平下调,此外,还会引起ERK1/ERK2磷酸化水平上调并且TGFβ通路激活。值得注意的是,单独用药时,有些通路蛋白磷酸化变化不显著,在联合用药时变得显著。如JAK/STAT、NF-κB、TGFβ通路。与单独用药相比,还会显著增强MAPK和JAK-STAT通路蛋白的磷酸化水平。通过磷酸化芯片的结果,发现22个磷酸化蛋白的变化与肿瘤的信号通路相关,尤其是活化ERK1/ERK2和TGFβ通路,表明联合用药可以诱导GBM细胞在体外进入衰老状态。




4、二甲双胍和辛伐他汀联合用药改变了GBM细胞中SASP相关基因表达水平和剪接体


首先,通过微流控qPCR在用二甲双胍和/或辛伐他汀处理的细胞中测量了32个关键SASP相关基因。在正常细胞中没有显著变化而在GBM细胞系中基因表达发生显著变化。SASP相关基因保留TOP20进行后续的热图分析,PLS-DA分析及后续的变量基因重要性的评分,发现最为重要的四个基因,即IL-6,CXCL3,CCR3,CDKN2D。随后,研究了四个之前报道的四个剪接体(SRSF3,RBM22,PTBP1,RBM3)的用药前后的变化。GBM细胞系,在用药后,四个剪接体均有不同程度的下调,药物联用时,下调更为显著。



5、二甲双胍和/或辛伐他汀处理的细胞的条件培养基诱导GBM细胞的衰老和端粒伸长


GBM细胞联合用药处理后的条件培养基可以使GBM细胞衰老或者是衰老相关的特征,如端粒变长。




6、二甲双胍和/或他汀类药物治疗对胶质瘤患者总生存期有显著延长


为了验证两种药物在临床上的可行性,选取四期GBM患者和三期星形胶质瘤患者进行临床试验,结果表明没有用药组生存期为12.2月,二甲双胍组为13.0月,辛伐他汀13.8月,联合用药组为15.5月。此外还进行了小鼠模型的验证。








讨论 & 结论

Discussion & Conclusion


本文利用RayBio磷酸化芯片(AAH-PPP-1,55个磷酸化蛋白)检测药物作用后各种磷酸化通路中关键蛋白的表达发现,二甲双胍和辛伐他汀,特别是它们的联合用药,在癌细胞中不仅限于侵袭性特征的改变(即增殖/迁移速率、肿瘤球/集落形成、细胞周期停滞、VEGF分泌和细胞凋亡诱导)还包括诱导衰老以及调节参与SASP和剪接机制的关键基因的表达,这可能促进衰老状态,端粒延长和GBM细胞侵袭行为的减弱。这些发现表明,二甲双胍和辛伐他汀,特别是它们的联合使用,作为一种潜在的新治疗工具,具有治疗GBM的极大潜力






更多专题…

点击链接 或 来电咨询:020-29891010














近期优惠活动

点击链接了解详情▼









RayBio®抗体芯片近期部分学术引用

Year Journal 2023 IF Article  Title
2017 Nature  Communications 16.6 Application of bio-orthogonal proteome labeling to cell   transplantation and heterochronic parabiosis
2017 Nature  Immunology 30.5 Direct control of regulatory T cells by keratinocytes
2017 Nature 64.8 Cytoplasmic chromatin triggers inflammation in senescence and   cancer
2017 Nature  Medicines 82.9 Dickkopf-1 promotes hematopoietic regeneration via direct and   niche-mediated mechanisms
2018 Acta  Biomaterialia 9.7 Manipulation of the response of human endothelial  colony-forming cells by focal adhesion assembly using gradient nanopattern  plates
2018 Journal  for Immuno Therapy of Cancer 10.9 Randomized phase II trial of autologous dendritic cell vaccines   versus autologous tumor cell vaccines in metastatic melanoma 5-year  follow up  and additional analyses
2018 Arthritis  & Rheumatology 13.3 Myogenic Progenitor Cells Exhibit Type I Interferon–Driven  Proangiogenic Properties and Molecular Signature During Juvenile  Dermatomyositis
2018 Hepatology 13.5 Identification and Therapeutic Intervention of Coactivated   Anaplastic Lymphoma Kinase, Fibroblast Growth Factor Receptor 2, and  Ephrin  Type-A Receptor 5 Kinases in Hepatocellular Carcinoma
2018 Hepatology 13.5 Sphingosine kinase 1 promotes liver fibrosis by preventing   miR-19b-3p-mediated inhibition of CCR2
2018 Cell  Host & Microbe 30.3 Listeria Adhesion Protein Induces Intestinal Epithelial Barrier   Dysfunction for Bacterial Translocation 
2018 Cell 64.5 CD10+ GPR77+ cancer-associated fibroblasts promote cancer   formation and chemoresistance by sustaining cancer stemness
2019 Theranostics 12.4 Monoclonal Antibody againstCXCL1 (HL2401) as a Novel Agent in  Suppressing IL6 Expression and Tumoral Growth
2019 Neurology 9.9 Changes in cerebralautoregulation and blood biomarkers after  remote ischemic preconditioning
2019 Nature  Communications 16.6 Altered respiratory virome and serum cytokine profile   associated with recurrent respiratory tract infections in children
2019 Nature  Communications 16.6 Microenvironmental IL1β promotes breast cancer metastatic   colonisation in the bone via activation of Wnt signalling
2019 Nature  Cell Biology 21.3 NAD+ metabolism governs the proinflammatory  senescence-associated secretome
2019 Nature  Medicine 82.9 Stress–glucocorticoid–TSC22D3 axis compromises therapy-induced  antitumor immunity
2019 Cell  Research 44.1 Sodium oligomannate therapeutically remodels gutmicrobiota and  suppresses gut bacterial amino acids-shaped neuroinflammation toinhibit  Alzheimer’s disease progression
2019 Cell 64.5 Regional activation of myosin II in cancer cells drives tumor  progression via a secretory cross-talk with the immune microenvironment
2020 Theranostics 12.4 Targeting the STING pathway in tumor-associated macrophages  regulates innate immune sensing of gastric cancer cells
2020 Theranostics 12.4 Plasma protein-based signature predicts distant metastasis and  inductionchemotherapy benefit in Nasopharyngeal Carcinoma
2020 Molecular  Therapy 12.4 HLSC-Derived Extracellular Vesicles Attenuate Liver Fibrosis  and Inflammation in a Murine Model of Non-alcoholic Steatohepatitis
2020 Acta  Pharmaceutica Sinica B 14.5 Chrysin serves as a novel inhibitor of DGKa/FAK interaction to  suppress the malignancy of esophageal squamous cellcarcinoma (ESCC)
2020 Journal  of Extracellular Vesicles 16 Small extracellular vesicles derived from human mesenchymal  stromal cells prevent group 2 innatelymphoid cell-dominant allergic airway  inflammation through delivery ofmiR-146a-5p
2020 Nature  Communications 16.6 Distinct effects of generalanesthetics on lung metastasis  mediated by IL-6/JAK/STAT3 pathway in mouse models
2020 Molecular  Cell 16.6 Ectosomal PKM2 Promotes HCC by Inducing Macrophage  Differentiation and Remodeling the Tumor Microenvironment
2020 Immunity 32.4 Excessive polyamine generation in keratinocytes promotes   self-RNA sensing by dendritic cells in psoriasis
2021 Pharmacological  Research 9.3 Affiliated Hospital of Integrated Traditional Chinese and  WesternMedicine, Nanjing University of Chinese Medicine
2021 Theranostics 12.4 Intravenous transplantationof olfactory ensheathing cells  reduces neuroinflammation after spinal cordinjury via interleukin-1 receptor  antagonist
2021 Theranostics 12.4 Tumor suppressor DRD2 facilitates M1 macrophages and restricts  NF-κB signaling to trigger pyroptosis in breast cancer
2021 Hepatology 13.5 Group-2 Innate LymphoidCells Promote Hepatocellular Carcinoma  Progression via CXCL2-Neutrophil Induced Immunosuppression
2021 Nature  Cell Biology 21.3 m6A-independent  genome-wide METTL3 and METTL14  redistribution drives the  senescence-associated secretory phenotype
2021 Signal  Transduction and Targeted Therapy 39.3 Mutant KRAS triggers functional reprogramming of  tumor-associated macrophages in colorectal cancer
2021 Cancer  Cell 50.3 Three subtypes of lung cancer fibroblasts define distinct  therapeutic paradigms
2022 Journal  for ImmunoTherapy of Cancer 10.9 Longitudinal plasma proteomic profiling of patients with  non-small cell lung cancer undergoing immune checkpoint blockade
2022 PNAS 11.1 Plasma metabolome and cytokine profile reveal glycylproline  modulating antibody fading in convalescent COVID-19 patients
2022 Advanced  Science 15.1 Mouse Modeling Dissecting Macrophage–BreastCancer Communication  Uncovered Roles of PYK2 in Macrophage Recruitment andBreast Tumorigenesis
2022 Nature  Microbiology 28.3 Multi-omics analyses of airway host–microbe interactions in  chronic obstructive pulmonary disease identify potential therapeutic  interventions
2023 Nature  Metabolism 20.8 TREM2hi  resident macrophages protect the septic heart by maintaining cardiomyocyte  homeostasis
2023 Journal  of Hematology & Oncology 28.5 LCN2 secreted by tissue-infiltrating neutrophils induces the  ferroptosis and wasting of adipose and muscle tissues in lung cancer cachexia
2023 Cancer cell 50.3 Tissue  factor is a critical regulator of radiation therapy-induced glioblastoma  remodeling






| /15

| 6

|

|

|    






RayBiotech


RayBiotech>3SCI10,00047,001>54,167>10395>2058RayBiotechELISA











【声明】内容源于网络
0
0
丰信生命科学
内容 0
粉丝 0
丰信生命科学
总阅读0
粉丝0
内容0